Greenwich LifeSciences, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. The unaudited statements are for a clinical-stage biopharmaceutical company developing GLSI-100 (GP2 plus GM-CSF), an immunotherapy intended to prevent breast cancer recurrence. The company reported no revenue.
Financial results and liquidity
| Metric | Three months ended Sept. 30, 2023 | Nine months ended Sept. 30, 2023 | Prior-year comparison |
|---|---|---|---|
| Revenue | $0 | $0 | $0 in both comparable 2022 periods |
| Research and development | $2.16 million | $5.37 million | Up 25% and 34%, respectively |
| General and administrative | $345,000 | $1.13 million | Down 48% for the quarter; roughly flat for nine months |
| Net loss | $2.39 million | $6.15 million | Compared with $2.32 million and $5.03 million |
| Net loss per share | $0.19 | $0.48 | Compared with $0.18 and $0.39 |
| Net cash used in operating activities | — | $4.32 million | $4.03 million for nine months of 2022 |
At September 30, cash was $9.14 million, down from $13.47 million at December 31, 2022. Total liabilities were $297,000, versus $263,000 at year-end; the filing reports no material debt balance. Stockholders’ equity was $8.85 million. No investing or financing cash flows were reported for the first nine months of 2023; the prior-year period included $7.54 million of stock repurchases. Gross margins are not applicable because the company had no revenue.
Changes, outlook, and risks
- Higher clinical expenses drove the increase in R&D and were identified as the primary reason the nine-month net loss increased. Quarterly G&A fell mainly due to lower compensation, financing, and corporate expenses.
- The company has commenced Flamingo-01, a Phase III trial of GLSI-100. Management expects current cash to fund planned operations for 12 months from issuance of the financial statements, but says additional capital will be required for long-term operating needs; future equity or debt financing is not assured. Management expects continued losses and significant expenses.
- Stock-based compensation was $1.78 million for the nine months. The company had 1,498,128 outstanding options, with future expense dependent on vesting, including performance milestones.
- Key disclosed risks include clinical-trial execution and regulatory approval, foreign-trial and licensing challenges, reliance on third parties for manufacturing and GM-CSF supply, and potential effects of inflation, recession, and COVID-19. The company reported no material legal proceedings and no off-balance-sheet arrangements.
- Management reported material weaknesses in internal controls, citing limited segregation of duties and insufficient written accounting, IT, and financial-reporting policies. The filing’s evaluation paragraph says controls were ineffective “as of September 30, 2022,” although it describes the evaluation as being at the end of the period covered by this report; the date should be checked against the filed version.
Important facts for investors to verify
- Flamingo-01 enrollment, timing, costs, and any subsequent trial or regulatory updates.
- Cash burn and whether financing will be needed sooner than management’s stated 12-month planned-operations runway.
- Availability and continuity of GM-CSF and other clinical-trial supplies, including arrangements with third-party manufacturers.
- Remediation progress for the disclosed internal-control material weaknesses and the apparent 2022 date in the controls evaluation.
- Future stock-based compensation expense and the vesting or performance conditions attached to outstanding options.